{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T14:04:05Z","timestamp":1781273045963,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016109","name":"Taishan Industry Leading Talents","doi-asserted-by":"publisher","award":["tscx202312146"],"award-info":[{"award-number":["tscx202312146"]}],"id":[{"id":"10.13039\/501100016109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD1800504"],"award-info":[{"award-number":["2025ZD1800504"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204221"],"award-info":[{"award-number":["82204221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejmech.2026.118824","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:49:23Z","timestamp":1775180963000},"page":"118824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual BRD4\/AKT inhibition overcomes c-MYC-driven resistance in metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"311","author":[{"given":"Fuao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118824_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","article-title":"The treatment landscape of metastatic prostate cancer","volume":"519","author":"Yamada","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118824_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2021","key":"10.1016\/j.ejmech.2026.118824_bib3","first-page":"7","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118824_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2021.08.033","article-title":"Chemotherapy in metastatic castration-resistant prostate cancer: current scenario and future perspectives","volume":"523","author":"Ruiz de Porras","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118824_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2019.07.013","article-title":"Efficacy of novel bromodomain and extraterminal inhibitors in combination with chemotherapy for castration-resistant prostate cancer","volume":"4","author":"V\u00e1zquez","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118824_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejmech.2026.118824_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118824_bib8","doi-asserted-by":"crossref","first-page":"563.e1","DOI":"10.1016\/j.clgc.2021.07.014","article-title":"Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer: a review article","volume":"19","author":"Cham","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ejmech.2026.118824_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2020.04.058","article-title":"Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer","volume":"78","author":"Herberts","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2026.118824_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118824_bib11","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-022-29655-0","article-title":"Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors","volume":"13","author":"Savill","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118824_bib12","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1038\/s41467-018-07258-y","article-title":"Targeting the BRD4\/FOXO3a\/CDK6 axis sensitizes AKT inhibition in luminal breast cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118824_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41467-020-20400-z","article-title":"BET inhibition disrupts transcription but retains enhancer-promoter contact","volume":"12","author":"Crump","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118824_bib14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118824_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114103","article-title":"Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial","volume":"205","author":"Rescigno","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118824_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118824_bib17","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1038\/s41388-022-02482-9","article-title":"AKT-mTORC1 reactivation is the dominant resistance driver for PI3K\u03b2\/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors","volume":"41","author":"Dunn","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118824_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108744","article-title":"An acetyl-histone vulnerability in PI3K\/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors","volume":"34","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2026.118824_bib19","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118824_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/epi.14.91","article-title":"Targeting BET bromodomains for cancer treatment","volume":"7","author":"Jung","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.ejmech.2026.118824_bib21","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1021\/acsmedchemlett.0c00294","article-title":"Identification of 3,5-Dimethylisoxazole derivatives as BRD4 inhibitors for the treatment of colorectal cancer","volume":"11","author":"Yang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118824_bib22","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1021\/acs.jmedchem.1c02165","article-title":"Discovery of potent, selective, and in vivo efficacious AKT kinase protein degraders via structure-activity relationship studies","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118824_bib23","doi-asserted-by":"crossref","first-page":"15959","DOI":"10.18632\/oncotarget.7557","article-title":"Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer","volume":"7","author":"De Velasco","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118824_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nchembio.183","article-title":"Inhibitor hijacking of Akt activation","volume":"5","author":"Okuzumi","year":"2009","journal-title":"Nat. Chem. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:46:05Z","timestamp":1781271965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"alternative-id":["S0223523426002692"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118824","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual BRD4\/AKT inhibition overcomes c-MYC-driven resistance in metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118824"}}